Drug screening system for targeting hippo signalling pathway-related tumours
Abstract
The World Health Organization reports that cancer is the leading cause of death worldwide. There is an urgent need
to develop new targeted medicines to provide patients with more precise treatment options.
The Hippo signaling
pathway is a key regulator of organ size and tissue homeostasis in animals, and its dysfunction is one of the
potential causes of cancer in many organs.
In our project, we engineered E. coli to produce two key components (MST2
and STRN3) of the human hippo pathway, the interaction of which leads to dysfunctional hippo pathway signaling. We
used this to develop a drug screening system to screen drug candidates that can restore normal Hippo signaling.
This
will contribute to the development of drugs targeting the Hippo pathway, improve the precision of oncology drugs,
and alleviate the suffering of patients.
